Our Purpose
The Clinical Proteomics Platform aims to exploit the latest technological developments in mass spectrometry and immunoassay for the discovery, validation and use of biomarkers in various human pathologies (proteins, RNA, DNA, metabolites).
Our Approach
Several technological approaches oriented towards the use of clinical samples and high throughput are available, including mass spectrometry (MRM and HRMS) and ultra-sensitive immunoassays (SIMOA and MSD).
Our Mission
Integrated in the Montpellier Proteome Cluster since its creation and IBiSA labeled, its mission is equally to make medical, biological and technical expertise in Clinical Proteomics available to academic and industrial teams. The PPC has been ISO 9001 certified since 2014.
Latest news :
Doctor Stéphane Muccio
Yesterday, Stéphane successfully defended his thesis on the subject of the hybrid LBA-LCMS technique (capture by immuno-affinity combined with liquid chromatography-mass spectrometry) for the analysis and quantification of biomarkers and therapeutic or anti-drug...
NULISA: a new technologie at the lab
Big news of the month; the arrival of the Alamar ARGO HT NULISA™ system, a major technological advance for the detection of previously inaccessible biomarkers. This technology enables the simultaneous analysis of up to 250 proteins, including critical biomarkers such...
CSF Society 2024
This year's CSF Society conference was attended by a MIRIADE E.U. reunion in Barcelona! Charlotte Teunissen, Pablo Mohaupt and Anna Wojdała Wojdala gave an overview of the MIRIADE consortium structure, and the remarkable achievements since the project commencement....
The PPC in a nutshell :
Employees
Years of experience
Ongoing projects
Patents
Clinical Proteomics Platform
Institute for Regenerative Medicine & Biotherapy (IRMB)
Hôpital Saint Eloi
80 rue Augustin Fliche
34295 MONTPELLIER – Cedex 5
FRANCE